Kailera Therapeutics, Inc. (KLRA) IPO — S-1 Filing, Stock & Insider Activity

Kailera Therapeutics, Inc. IPO — Status & S-1 Filing

Ticker: KLRA
Status: Priced — IPO complete
S-1 filed: 2026-03-27
Effective: 2026-04-16
IPO / pricing date: 2026-04-17
Exchange: NASDAQ
Expected price range: $14.00–$16.00
Shares offered: 39,062,500
SEC CIK: 0002096997 · View the S-1 on SEC EDGAR →

Track every registration update on the InsiderAlpha IPO tracker.

Updated Jul 16, 2026 · Last SEC filing 2026-07-08

Kailera Therapeutics, Inc. (KLRA) has filed 19 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-08. 2 Form 8-K material event filings were reported by KLRA in the last 90 days. InsiderAlpha tracks every KLRA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Kailera Therapeutics, Inc. (KLRA)

SEC CIK	0002096997

90-Day SEC Filing Activity

Form 4 filings (90d)	19
Form 8-K filings (90d)	2
Latest Form 4 filing	2026-07-08

Recent KLRA Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-09	Renaud Ronald C JR	CEO & President	M — Option exercise	38.1K	$5.25	$200K	SEC
2026-04-20	BAIN CAPITAL INVESTORS LLC	Insider	P — Open-market purchase	8.40M	$16.00	$134.38M	SEC
2026-04-20	Koppel Adam	Insider	J — Other acquisition / disposition	16.88M	—	—	SEC
2026-04-20	Koppel Adam	Insider	J — Other acquisition / disposition	4.15M	—	—	SEC
2026-04-20	Koppel Adam	Insider	P — Open-market purchase	1.56M	$16.00	$25.00M	SEC
2026-04-20	Bain Capital Life Sciences Investors, LLC	Insider	J — Other acquisition / disposition	16.88M	—	—	SEC
2026-04-20	Bain Capital Life Sciences Investors, LLC	Insider	J — Other acquisition / disposition	4.15M	—	—	SEC
2026-04-20	BAIN CAPITAL INVESTORS LLC	Insider	J — Other acquisition / disposition	17.86M	—	—	SEC
2026-04-20	Kaplan Andrew T.	Insider	J — Other acquisition / disposition	17.86M	—	—	SEC
2026-04-20	Kaplan Andrew T.	Insider	P — Open-market purchase	8.40M	$16.00	$134.38M	SEC
2026-04-20	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	10% Owner	J — Other acquisition / disposition	9.48M	—	—	SEC
2026-04-20	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	10% Owner	J — Other acquisition / disposition	2.03M	—	—	SEC
2026-04-20	RTW INVESTMENTS, LP	Insider	J — Other acquisition / disposition	10.28M	—	—	SEC
2026-04-20	RTW INVESTMENTS, LP	Insider	P — Open-market purchase	500.0K	$16.00	$8.00M	SEC
2026-04-20	Bain Capital Life Sciences Investors, LLC	Insider	P — Open-market purchase	1.56M	$16.00	$25.00M	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Kailera Therapeutics, Inc. (KLRA). Updated in real time as new filings are submitted to the SEC.

Most-Active KLRA Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Koppel Adam	6	$25.00M
Bain Capital Life Sciences Investors, LLC	5	$25.00M
Renaud Ronald C JR	4	$200K
RTW INVESTMENTS, LP	4	$8.00M
Kaplan Andrew T.	4	$134.38M

Recent KLRA Form 8-K Material Events

2026-05-26 — Item 2.02, 9.01 [SEC]
2026-04-20 — Item 5.03, 8.01, 9.01 · Other · neutral [SEC]
Kailera Therapeutics filed an amended and restated certificate of incorporation on April 20, 2026, in connection with the closing of its initial public offering. The restated certificate implements standard post-IPO governance changes including authorized share increases, elimina

Recent Insider Filings

2026-07-08 — Tregoning Kathleen (See Remarks)
2026-06-11 — Renaud Ronald C JR (CEO & President)
2026-04-22 — RTW INVESTMENTS, LP (Insider)
2026-04-22 — Jiangsu Hengrui Pharmaceuticals Co., Ltd. (10% Owner)
2026-04-20 — BAIN CAPITAL INVESTORS LLC (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in KLRA insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

KLRA Insider Trading — FAQ

What is the latest insider trade for KLRA?: Kailera Therapeutics, Inc. (KLRA) had 19 insider filings in the last 90 days, with the most recent on 2026-07-08. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying KLRA stock?: 0 insider purchases of KLRA were filed in the last 90 days.
How many insiders are selling KLRA stock?: 0 insider sales of KLRA were filed in the last 90 days.
Where can I see KLRA SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every KLRA SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live KLRA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.